VPH NoE

The Virtual Physiological Human Network of Excellence (VPH NoE) proposal has been designed with 'service to the community' of VPH researchers as its primary purpose. Its aims range from the development of a VPH ToolKit and associated infrastructural resources, through integration of models and data across the various relevant levels of physiological structure and functional organisation, to VPH community building and support. The VPH NoE aims to foster the development of new and sustainable educational, training and career structures for those involved in VPH related science, technology and medicine, and will lay the foundations for a future Virtual Physiological Human Institute.

The VPH NoE constitutes a leading group of universities, institutes and organisations who will, by integrating their experience and ongoing activities in VPH research, promote the creation of an environment that actively supports and nurtures interdisciplinary research, education, training and strategic development. The VPH NoE will lead the coordination of diverse activities within the VPH initiative to deliver: new environments for predictive, patient-specific, evidence-based, more effective and safer healthcare; improved semantic interoperability of biomedical information and contribution to a common health information infrastructure; facile, on-demand access to distributed European computational infrastructure to support clinical decision making; and increased European multidisciplinary research excellence in biomedical informatics and molecular medicine by fostering closer cooperation between ICT, medical device, medical imaging, pharmaceutical and biotech companies.

The VPH NoE will connect the diverse VPH projects, including not only those funded as part of the VPH initiative but also those of previous EC frameworks and national funding schemes, together with industry, healthcare providers, and international organisations, thereby ensuring that these impacts will be realised.

For further information, please visit:
http://www.vph-noe.eu

Project co-ordinator:
University College London (UCL)

Partners:

  • Institut Municipal d'Assistència Sanitària (IMAS)
  • Centre National de la Recherche Scientifique (CNRS)
  • The University of Nottingham
  • Europäisches Laboratorium für Molekularbiologie EMBL
  • The Chancellor, Master and Scholars of the University of Oxford
  • GEIE ERCIM
  • The University of Sheffield
  • Universitat Pompeu Fabra
  • Université Libre de Bruxelles
  • Institut National de Recherche en Informatique et en Automatique
  • The University of Auckland
  • Karolinska Institutet

Timetable: from 06/2008 - to 11/2012

Total cost: € 9.649.516

EC funding: € 7.999.367

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Networks of Excellence


Related news article:

Most Popular Now

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

Bayer Acquires Blackford Analysis Ltd. B…

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...

Veradigm Announces Strategic Investment …

Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million...